CTI Announces Data Presentations at the 18th Congress of the European ... The Herald | HeraldOnline.com The SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the ... |
